GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...

The differing time–action profiles provided by these long-acting MPH formulations may allow clinicians to target specific periods of the day that are particularly relevant for a patient ...

Discrimination against older workers cost the US economy an estimated $850 billion in GDP in 2018, according to a 2020 report ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Biologics are incredibly powerful and targeted. For these reasons, pharmaceutical companies have invested a lot of time and money over the past 20 years developing medications based on these ...

Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 inflammation, according to phase 3 clinical trials.

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.